BioSpace News Archive

UCB, a global biopharmaceutical company, today announced new data on its TNF inhibitor, CIMZIA® (certolizumab pegol), and investigational IL-17A and IL-17F inhibitor, bimekizumab.

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host an investor call with a live Q&A on Monday, November 9th at 8:30 a.m. EST to provide additional details on the clinical and immune response data from the remaining GEN-009 Part B patients to be shared at the 35th Annual Meeting of The Society

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN) (OTCQX: IMLFF), today announced that, due to the regulatory quiet period the Company is in, it has rescheduled the reporting of its financial results for the first quarter of fiscal year 2021, ending September 30, 2020.

“Supply from the facility is critical, and by supporting one of our global partners in the oncology field, we are enabling the treatment of many cancer patients.

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, reported financial results for the third quarter ended September 30, 2020 and provided a review of recent business and clinical highlights.

U.S. LINZESS® (linaclotide) net sales increased 10% year-over-year to $241 million, as reported by AbbVie Inc. (AbbVie)

World Health Organization Director - General Dr. Tedros Adhanom Ghebreyesus will address the 4th Annual ConVerge2Xcelerate 2020 Symposium, November 10 - 11, themed “US-World Health Transformation.”.

First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (“ADPKD”)

Owens & Minor, Inc. announced that the company will participate in the 29th Annual Credit Suisse Healthcare Conference on November 12, 2020.

TransEnterix, Inc., a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, announced its operating and financial results for the third quarter of 2020.